Search results for "Cardiac"

Caspase 9 and Caspase 3 Immunohistochemical Reactivity Pattern in Skeletal and Cardiac Muscle at Different Times After Death: A New Tool for Postmort…

Learning Overview: After attending this presentation, attendees will understand the importance of the identification of new markers that could be used as possible PMI indicators, especially in contexts in which the reliance on the classic thanatochronological triad—livor, rigor, and algor mortis—is not conclusive. Impact on the Forensic Science Community: This presentation will impact the forensic science community by highlighting the relationship between the activation pattern of caspases 9 and 3 on skeletal and cardiac muscle samples and PMI. The determination of the amount of time elapsed from one’s death to the recovery of the body—the so-called PMI—has always relied on the evaluation o…

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and …

2016

WOS: 000393031600001

Asymptomatic ventricular pre-excitation in children.

2009

ASYMPTOMATIC VENTRICULAR PREEXCITATION IN CHILDREN OBJECTIVE: This retrospective study was planned for a good risk assessment of asymptomatic patients affected by ventricular pre-excitation. METHODS: From 1985 to 2007, 124 patients with an atrioventricular pathway (electrocardiographic signs of ventricular pre-excitation) were admitted to our cardiology division. The average age was 7 years (range 1 month to 18 years). The mean follow-up period in the whole population of patients was 4.2 years (range 1-13 years). Four patients were lost during the follow-up. During this period, all patients remained in good health. In all of them, we performed a Holter evaluation every year. An intermittent…

Recommendations of the European Cardiac Arrhythmia Society Committee on Device Failures and Complications

2006

Recommendations of the European Cardiac Arrhythmia Society Committee on Device Failures and Complications MASSIMO SANTINI,* JOHANNES BRACHMANN,† RICCARDO CAPPATO,‡ WYN DAVIES,§ JERONIMO FARRE,‖ SAMUEL LEVY,¶ AURELIO QUESADA,# RENATO P. RICCI,** EDWARD ROWLAND,†† NEIL SULKE‡‡ From *San Filipo Neri Hospital, Rome, Italy, †Klinikum Coburg, Germany, ‡Policlinico S. Donato, Milan, Italy, §St. Mary Hospital, London, UK, ‖Fundacion Jimenez Diaz, Madrid, Spain, ¶Hopital Nord des Bourrellys, Marseille, France, #Hospital General University of Valencia, Spain, **San Filippo Neri Hospital, ††St. George Medical School, London, UK, ‡‡Eastbourne General Hospital, Sussex, UK

Active-fixation coronary sinus pacing lead extraction: A hybrid approach

2012

Cardiac resynchronization therapy (CRT) can be considered as the standard treatment for patients suffering from heart failure (NYHA III–IV), severely reduced left ventricular (LV) function, and wide QRS complexes. Over the past years, the lead systems used to stimulate the left ventricle have evolved technically from epicardial approaches to a transvenous access accompanied by a significant reduction of procedure-related complication rates [1]. However, even today, LV dislodgement rates ranging 5–10% and the instability of thresholds over time remain the greatest challenges with transvenous LV leads in CRT. Therefore, a special LV lead utilizing active fixation (the Attain StarFix® active f…

Cardiovascular magnetic resonance characterization of a hamartoma in an asyntomatic child

2009

Abstract Background The prevalence of primary cardiac neoplasms is approximately 0.3% and these masses should be distinguished from many of other primary and secondary processes that can occur in the heart. Further assessment of the left ventricular mass presents important clinical implications. Cardiovascular magnetic resonance was used. Clinical case An asyntomatic 12-year-old child was referred for cardiovascular magnetic resonance imaging to further assess a left ventricular mass found after an echocardiography, executed for assessment for sport activity. His past medical history was absolutely negative. The patient was in optimal state of health. The EKG showed an aspecific ST elevatio…

Perlecan is critical for heart stability

2008

Aims Perlecan is a heparansulfate proteoglycan found in basement membranes, cartilage, and several mesenchymal tissues that form during development, tumour growth, and tissue repair. Loss-of-function mutations in the perlecan gene in mice are associated with embryonic lethality caused primarily by cardiac abnormalities probably due to hemopericards. The aim of the present study was to investigate the mechanism underlying the early embryonic lethality and the pathophysiological relevance of perlecan for heart function. Methods and results Perlecan-deficient murine embryonic stem cells were used to investigate the myofibrillar network and the electrophysiological properties of single cardiomy…

Immunohistochemical detection of early myocardial infarction: a systematic review

2017

The postmortem diagnosis of early myocardial infarction is a challenge for forensic pathologists because the routine histology is neither specific. Many authors have suggested the use of the immunohistochemistry to fill the gaps in the histological diagnosis of early myocardial infarction. This review aims to analyse advances of immunohistochemical detection of early cardiac damage due to ischaemia. To this purpose, we reviewed experimental studies that investigated immunohistochemical markers and their estimated timing of expression. The review was performed according to specific inclusion and exclusion criteria, and a total of 23 studies assessing the immunohistochemical markers for the d…

Isolation and Characterization of CD276+/HLA-E+ Human Subendocardial Mesenchymal Stem Cells from Chronic Heart Failure Patients: Analysis of Differen…

2012

Mesenchymal stem cells (MSCs) are virtually present in all postnatal organs as well as in perinatal tissues. MSCs can be differentiated toward several mature cytotypes and interestingly hold potentially relevant immunomodulatory features. Myocardial infarction results in severe tissue damage, cardiomyocyte loss, and eventually heart failure. Cellular cardiomyoplasty represents a promising approach for myocardial repair. Clinical trials using MSCs are underway for a number of heart diseases, even if their outcomes are hampered by low long-term improvements and the possible presence of complications related to cellular therapy administration. Therefore, elucidating the presence and role of MS…

MicroRNA and Cardiac Stem Cell Therapy

2012

Cardiac Progenitor Cells (CPCs) are multipotent cells of the myocardium. They are located inside niches of the heart muscle, can be isolated, characterized and used for cardiac regeneration in stem cell therapy. Actually, CPCs may be isolated by tissue digestion with or without cell sorting, but it is difficult to achieve the maximum level of differentiation when these cells are implanted into a damaged myocardium. The knowledge recently acquired on small molecules of non-coding RNAs, microRNA (miRNA), may improve the use of these cells in stem cell therapy. In fact, these small molecules may be attached to devices or adminstered as they are or in combination with nanoparticles in order to …